Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-PanTumor01 phase 2 study of raludotatug deruxtecan in advanced or metastatic solid tumors
CTR20250888Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of raludotatug deruxtecan in endometrial cancer (EC), Cervical Cancer (CC), ovarian cancer, transitional cell carcinoma (TCC), renal cell carcinoma (RCC), sponsored by Daiichi Sankyo Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
raludotatug deruxtecan
03
Conditions
endometrial cancer (EC)Cervical Cancer (CC)ovarian cancertransitional cell carcinoma (TCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20250888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250888.